Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections
Status:
Completed
Trial end date:
2020-07-30
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the effect of topical prophylaxis with brinzolamide-brimonidine
fixed combination on short-term intraocular pressure (IOP) elevation after intravitreal
injections of anti-vascular endothelial growth factors (anti-VEGF).
Patients scheduled for treatment with intravitreal injections of anti-VEGF will be randomly
divided into two groups. In control group no prophylactic medication will be used, whereas in
case group one drop of brinzolamide-brimonidine fixed combination will be instilled two hours
before the injection. IOP will be measured before the injection, 1 minute after the
injection, 10 minutes and 30 minutes post-injection in all eyes. In case group, the
pre-injection IOP will be measured prior to the administration of the fixed combination of
brinzolamide-brimonidine. The iCare (IC200) tonometer will be used for IOP measurements at
all time points.